Dentons Advises ADEL on Exclusive Worldwide License Agreement with Sanofi for ADEL-Y01, a novel antibody therapy for Alzheimer’s disease

SEOUL / PITTSBURGH-March 26, 2026-Dentons advised ADEL, Inc., a Korean biopharmaceutical company focused on discovery and development of therapies for neurodegenerative diseases including Alzheimer's disease, on its exclusive worldwide license agreement with Sanofi for the development and commercialization of ADEL-Y01, a tau-targeting therapeutic for Alzheimer's disease.

Under the agreement, ADEL granted Sanofi exclusive worldwide rights to develop and commercialize ADEL Y01, with ADEL receiving total potential consideration of up to US$1.04 billion, including a US$80 million non refundable upfront payment, additional development and commercial milestone payments, and tiered royalties on net sales up to double digit percentages. ADEL Y01 is currently in a Phase 1 clinical trial in the U.S. under an FDA approved IND.

Dentons advised ADEL in all significant aspects of the transaction, including deal structuring and negotiation, due diligence and intellectual property and patent counseling. The Dentons team advising ADEL included partner Bernard Ham and foreign attorney Jielle Han of Dentons Lee, together with partner Michael Dukes of Dentons US.

Reference article: ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com